Minretumomab information

Minretumomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
Other names	CC49
ATC code	V09IX03 (WHO) (125I radiolabelled);
Identifiers
CAS Number	195189-17-4 ;
ChemSpider	none;
UNII	235435CH6L;
	(what is this?) (verify)

Minretumomab (CC49) is a mouse monoclonal antibody^[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.^[2]^[3] Apparently, it never got past Phase I clinical trials for this purpose.^[4]

^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
^ "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
^ Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
^ "Studies found for: CC49". ClinicalTrials.gov.

[1] "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.

[2] "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.

[3] Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.

[4] "Studies found for: CC49". ClinicalTrials.gov.

Minretumomab information

and 2 Related for: Minretumomab information

Minretumomab

Naptumomab estafenatox